On the role of intensity-modulated radiation therapy in radiation oncology.
Physicists are critical members of the radiation therapy team, and rightfully so. Therefore, it is not unreasonable that they be acquainted with the broader aspects of the management of patients who receive radiation treatments, as well as the roles played by surgeons, medical oncologists and other members of the treatment team. The spate of recent technical developments openly embraced by medical physicists, many of whom appear unconcerned by questionable benefits and very high costs, leads the authors to believe that this acquaintance is not as widespread as it should be. The present paper provides a brief review of clinical considerations in radiation oncology, statistics for the most prevalent cancers, and how those cancers that account for over 90% of mortality are currently treated. With these data as background, it then considers the extent to which one of the more widely promoted new technologies is likely to impact upon survival. By providing this modicum of perspective, physicists will be in a better position to evaluate these new technologies in more fundamental clinical terms, and thereby enhance their contributions to the overall care of the cancer patient.
Schulz
R J
RJ
Department of Therapeutic Radiology, Yale University, Johnson, Vermont 05656, UDA.
Kagan
A Robert
AR
D018572:Disease-Free Survival; D006801:Humans; D009369:Neoplasms / Q000453:epidemiology / Q000401:mortality* / Q000532:radiotherapy*; D020266:Radiotherapy, Conformal / Q000191:economics / Q000379:methods* / Q000706:statistics & numerical data; D016896:Treatment Outcome